Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Retained Earnings (2018 - 2025)

Arcturus Therapeutics Holdings' Retained Earnings history spans 8 years, with the latest figure at -$514.6 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 14.66% year-over-year to -$514.6 million; the TTM value through Dec 2025 reached -$514.6 million, down 14.66%, while the annual FY2025 figure was -$514.6 million, 14.66% down from the prior year.
  • Retained Earnings reached -$514.6 million in Q4 2025 per ARCT's latest filing, down from -$485.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$200.2 million in Q1 2021 to a low of -$514.6 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$384.2 million, with a median of -$396.7 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: plummeted 177.78% in 2021, then rose 27.91% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$347.5 million in 2021, then increased by 2.69% to -$338.1 million in 2022, then dropped by 8.8% to -$367.9 million in 2023, then decreased by 21.99% to -$448.8 million in 2024, then fell by 14.66% to -$514.6 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Retained Earnings are -$514.6 million (Q4 2025), -$485.5 million (Q3 2025), and -$472.1 million (Q2 2025).